The company is a Korea-based company principally engaged in the vaccines and immunotherapy research business based on based on adjuvant platform technology. The Company is engaged in the research and development (R D) of premium preventive vaccines, therapeutic vaccines and immunotherapies such as hepatitis B virus (HBV) vaccines, chronic HBV vaccines and others. The Company is also engaged in the vaccines distribution and licensing out services. The Company was established on June 9, 2000. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on October 22, 2021.
Headquarters
407, 406, Byeoksan, 560, Dunchon-Daero, Jungwon-Gu
Seongnam; Gyeonggi;
Contact Details: Purchase the Cha Vaccine Research Institute Co.,Ltd. report to view the information.
Website: http://www.chavaccine.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service